Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SynT

Financiado

Generation, validation and use of a synthetic reporter of CAR T cell products fu...

Generation, validation and use of a synthetic reporter of CAR T cell products function and dysfunction "Cell-based immunotherapy, particularly adoptive cell transfer (ACT) using engineered T cells, holds great promise as a therapeutic strategy for cancer treatment. However, challenges such as the manufacturing process, excessive an... ver más

31/08/2025

MDC

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-02-05

ERC-2023-POC: ERC PROOF OF CONCEPT GRANTS Objective:Objectives:The ERC Proof of Concept Grants aim at facilitating exploration of the commerci...

I+D

Cerrada hace 1 año

0% 100% 100%

1 Participantes

MDC

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CAR-TIME Drivers and Brakes of CAR T Cell Efficacy Determined by the... 1M€ Cerrado

ArTCell Bottom-up manufacturing of artificial anti-tumor T cells 3M€ Cerrado

MetaboTract Improving cellular cancer immunotherapy using chemotactic me... 190K€ Cerrado

CATCH Novel T cell therapies against lymphocytic leukaemia 150K€ Cerrado

MiTE Developing the next generation of cis-targeting macrophage-T... 150K€ Cerrado

CNS2023-144236 Materiales para biomedicina 200K€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2024-02-05
Fecha Fin: 2025-08-31

Líder del proyecto

MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto "Cell-based immunotherapy, particularly adoptive cell transfer (ACT) using engineered T cells, holds great promise as a therapeutic strategy for cancer treatment. However, challenges such as the manufacturing process, excessive antigen exposure, and the hostile tumor microenvironment often lead to dysfunctional T cell products, limiting their effectiveness in treating both blood cancers and solid tumors. We propose a novel tool to define in vitro conditions to enhance T cell product fitness through the development of a synthetic reporter system for detecting T cell dysfunction states, referred to as SynT. This innovative system will incorporate a dual synthetic locus control region (sLCR) reporter, with one sLCR reporter indicating T cells in a potent ""serial killer"" mode and another sLCR reporter representing T cell dysfunction. By using SynT, we aim to screen for external signaling and pharmacological modulators that can enrich and reverse the dysfunctional state in CAR T cells. we will generate and validate a synthetic reporter of CAR T cell products function and dysfunction, and produce a media supplement that promotes ACT products functions. "

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores